Durvalumab is an immunotherapy treatment for bladder cancer. It is marketed under the brand name Imfinzi and manufactured by AstraZeneca. Durvalumab helps the immune system fight cancer, and clinical trials are testing it on a variety of cancers including mesothelioma.
Durvalumab was approved by the U.S. Food and Drug Administration (FDA) in May 2017 to treat late-stage bladder cancer. It is approved specifically to treat a form of bladder cancer called urothelial carcinoma that cannot be removed by surgery and has recurred after chemotherapy.
Clinical trials have tested the drug on patients with mesothelioma, lung cancer, melanoma, pancreatic cancer, gastric cancer, head and neck cancer, esophageal cancer, lymphoma, myelodysplastic syndrome and solid tumors.
The best results in these trials occurred in lung cancer patients.
A phase III clinical trial of durvalumab for stage 3 lung cancer patients reported the drug stopped tumor growth for an average of 11 months. Some patients showed no new tumor growth after chemotherapy and radiation therapy.
The FDA in July 2017 designated durvalumab as a breakthrough therapy, which expedites the development and review of the drug.
In October 2017, the FDA accepted AstraZeneca’s application to approve durvalumab for lung cancer treatment and is reviewing the drug for approval.
Promising results in lung cancer patients led to clinical trials testing durvalumab in the mesothelioma population.
In 2015, an Italian phase II trial began testing durvalumab in combination with tremelimumab on mesothelioma patients who did not qualify for surgery.
Around 62 percent of participants responded to durvalumab and tremelimumab, but the study failed to improve survival. Doctors leading the study said more research is necessary.
Several clinical trials in the U.S. and abroad are evaluating the effects of durvalumab in people with mesothelioma.
Durvalumab — like the immunotherapy drug Keytruda — is a checkpoint inhibitor that blocks PD-L1.
PD-L1 is a protein on the surface of cancer cells that works like a mask to hide cancer from the immune system.
Durvalumab blocks PD-L1 and essentially removes the mask so the immune system can identify and attack cancer cells.
10 mg/kg to 500 mg/mL
Checkpoint inhibitor, monoclonal antibody
Vaccines, vitamin E, zinc, cat’s claw, echinacea
A Phase 2 Study of durvalumab in Combination with Tremelimumab in Malignant Pleural Mesothelioma
Pneumonitis, liver disease, colitis, kidney inflammation, endocrine gland disease, infection, infusion reactions, fetal harm
We can help you find a durvalumab clinical trial actively enrolling mesothelioma patients.Get Help Now
Durvalumab stimulates the immune system and may cause it to attack healthy organs and tissues. Side effects range from mild to severe.
Mild side effects include:
Other mild side effects include reduced sodium in the blood and low white blood cell count.
Serious side effects of durvalumab include:
Signs of severe infusion reactions include chills or shaking, flushing, itching or rash, wheezing or shortness of breath, fever, dizziness or lightheadedness, facial swelling and back or neck pain.
Talk to your doctor immediately if you notice any mild or serious side effects. Seek medical treatment quickly to keep side effects under control.
Nearly all clinical trials of durvalumab involving mesothelioma patients are too new to produce results.
Only the Italian study that began in 2015 has published early results, which proved the drug was effective against mesothelioma but did not improve survival.
Other clinical trials began in 2016 and 2017.
In 2016, the Lung Institute at Baylor College of Medicine in Houston opened a trial that combines durvalumab with the immunotherapy drug tremelimumab. Participants in this trial, which is overseen by mesothelioma expert Dr. David Surgarbaker, must qualify for surgery.
Dana-Farber Cancer Institute in Boston began a phase II clinical trial in April 2017 that combines durvalumab and tremelimumab among patients who do not qualify for mesothelioma surgery.
A nationwide phase II trial began in June 2017 that combines durvalumab with chemotherapy as a first-line treatment for mesothelioma patients who do not qualify for surgery. The Seattle Cancer Care Alliance, a renowned mesothelioma treatment center, is participating in the trial.
Mesothelioma survivor and Navy veteran Jim McWhorter participated in Dana-Farber’s durvalumab clinical trial, and he initially responded well. His cancer stopped growing for several months. Then a CT scan showed the cancer was growing again, and McWhorter had to leave the trial in search of other options.
Research shows durvalumab works for many people with mesothelioma, but usually only for a period of time. Durvalumab may not be a cure for mesothelioma, but research is underway to investigate the roles it might play in controlling the cancer and improving survival.
Joining the team in February 2008 as a writer and editor, Michelle Whitmer has translated medical jargon into patient-friendly information at Asbestos.com for more than eight years. Michelle is a registered yoga teacher, a member of the Academy of Integrative Health & Medicine, and was quoted by The New York Times on the risks of asbestos exposure. Read More